Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015
(Thomson Reuters ONE) -
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company
with the mission of developing new therapies for unmet medical needs in the
field of cardiovascular diseases, will be participating at the 15(th) edition of
the European Large & Midcap Event, a conference dedicated to meetings between
European listed companies and institutional investors, to be held in Paris on
October 7 & 8, 2015.
On that occasion, Lionel Ségard, Chairman and CEO of Quantum Genomics, and
Marc Karako, Chief Financial Officer, will comment on the Company's latest
progress, in particular the Phase IIa clinical trials currently under way for
high blood pressure of its drug candidate QGC001 and in preparation stage for
the treatment of heart failure.
QGC001 is the first of a new class of therapeutics for the treatment of
complicated/resistant hypertension, called Brain Aminopeptidase A Inhibitors
(BAPAIs). The objective of QGC001 is to offer an alternative therapy for the
treatment of high blood pressure, aimed particularly at patients with a Low
Renin High Vasopressin (LRHV) hormonal profile.
+----------------------------------+-------------------------------------------+
|CONTACTS |ABOUT QUANTUM GENOMICS |
| | |
|Quantum Genomics |Quantum Genomics is a biopharmaceutical |
|Lionel Ségard |company with the mission of developing new |
|Chairman & Chief Executive Officer|therapies for unmet medical needs in the |
|+33 1 85 34 77 77 |field of cardiovascular diseases, |
| |especially high blood pressure and heart |
|Quantum Genomics |failure. |
|Marc Karako | |
|CFO - Investor Relations |Quantum Genomics is developing a new |
|+33 1 85 34 77 75 |therapeutic approach based on BAPAI (Brain|
|marc.karako(at)quantum-genomics.com |Aminopeptidase A Inhibition). This is the |
| |result of more than 20 years of academic |
|ACTUS finance & communication |research in the laboratories of the |
|Jean-Michel Marmillon |Collège de France, INSERM, CNRS and the |
|Press Relations |University of Paris Descartes. |
|+33 1 53 67 36 73 | |
|jmmarmillon(at)actus.fr |Quantum Genomics is listed on the Alternext|
| |market in Paris (ISIN code FR0011648971, |
| |Ticker ALQGC). |
| | |
+----------------------------------+-------------------------------------------+
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Quantum Genomics via GlobeNewswire
[HUG#1953569]
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2015 - 19:00 Uhr
Sprache: Deutsch
News-ID 421901
Anzahl Zeichen: 3827
contact information:
Town:
Massy
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 209 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
Quantum Genomics (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
